ES2040234T3 - Derivados del tetrahidronaftaleno y medicamentos que los contienen. - Google Patents

Derivados del tetrahidronaftaleno y medicamentos que los contienen.

Info

Publication number
ES2040234T3
ES2040234T3 ES198787116251T ES87116251T ES2040234T3 ES 2040234 T3 ES2040234 T3 ES 2040234T3 ES 198787116251 T ES198787116251 T ES 198787116251T ES 87116251 T ES87116251 T ES 87116251T ES 2040234 T3 ES2040234 T3 ES 2040234T3
Authority
ES
Spain
Prior art keywords
alkyl
dion
benzodiazepine
imidazo
interrupted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787116251T
Other languages
English (en)
Inventor
Quirico Dr. Branca
Roland Prof. Dr. Jaunin
Hans Peter Dr. Marki
Franzi Dr. Marti
Henri Prof. Dr. Ramuz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2040234T3 publication Critical patent/ES2040234T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

SE VERIFICARIA QUE EL NUEVO DERIVADO DE TETRAHIDRONAFTALIN DE LA FORMULA DONDE LOS SIMBOLOS A,X,N,R,R1,R2 Y R3 QUE POSEEN UN SIGNIFICADO DADO EN LA DEMANDA 1, TIENEN UN EFECTO ANTIARRITMICO Y MARCADAMENTE ANTAGONISTICO DE CALCIO Y PUEDEN UTILIZARSE POR CONSIGUIENTE COMO MEDICAMENTOS, ESPECIALMENTE PARA LA LUCHA O PREVENCION DE LA ANGINA DE PECHO, ISQUEMIA, ARRITMIA, ALTA PRESION DE SANGRE E INSUFICIENCIA CARDIACA. LAS COMBINACIONES DE LA FORMULA I PUEDEN FABRICARSE POR AMINACION DE UNA COMBINACION DE LA FORMULA, CON UNA AMINA DE ALQUIL N CORRESPONDIENTE Y DADO EL CASO ACILIACION O CONSIGUIENTE O TRANSFORMACION CON UN ISOCIANATO Y OXIDACION N.
ES198787116251T 1986-11-14 1987-11-04 Derivados del tetrahidronaftaleno y medicamentos que los contienen. Expired - Lifetime ES2040234T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH456586 1986-11-14

Publications (1)

Publication Number Publication Date
ES2040234T3 true ES2040234T3 (es) 1993-10-16

Family

ID=4278454

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787116251T Expired - Lifetime ES2040234T3 (es) 1986-11-14 1987-11-04 Derivados del tetrahidronaftaleno y medicamentos que los contienen.

Country Status (31)

Country Link
US (1) US4808605A (es)
EP (1) EP0268148B1 (es)
JP (1) JP2504490B2 (es)
KR (1) KR960004863B1 (es)
CN (1) CN1028991C (es)
AT (1) ATE70267T1 (es)
AU (1) AU600769B2 (es)
BG (1) BG60937B2 (es)
CA (1) CA1319144C (es)
CS (2) CS264350B2 (es)
DE (2) DE3775177D1 (es)
DK (1) DK171349B1 (es)
DZ (1) DZ1142A1 (es)
ES (1) ES2040234T3 (es)
FI (1) FI94414C (es)
GR (1) GR3004029T3 (es)
HK (1) HK110494A (es)
HU (1) HU215915B (es)
IE (1) IE60695B1 (es)
IL (1) IL84407A (es)
LV (1) LV5745B4 (es)
MC (1) MC1883A1 (es)
MX (1) MX173614B (es)
NL (1) NL970019I2 (es)
NO (2) NO172237C (es)
NZ (1) NZ222474A (es)
PH (1) PH23919A (es)
PT (1) PT86130B (es)
SG (1) SG114194G (es)
ZA (1) ZA878362B (es)
ZW (1) ZW20087A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003283A1 (en) * 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
CA2011461A1 (en) * 1989-03-20 1990-09-20 Urs Hengartner Tetrahydronaphthalene derivatives
NL9001522A (nl) * 1990-07-04 1992-02-03 Schreiner Luchtvaart Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen.
TW216770B (es) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5674863A (en) * 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
JP2941950B2 (ja) * 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド
DE69526073T2 (de) 1995-06-23 2002-08-22 Univ Delft Tech Verfahren zur Herstellung eines schäumbaren Filmes
TR199700018A2 (tr) * 1996-01-31 1997-08-21 Hoffmann La Roche Alfa,beta-doymamis organik karboksilik asitlerin imaline yönelik proses.
US5811556A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via a naphthalenylacetic acid
US5811557A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via an acetonitrile anion
US5808088A (en) * 1997-04-30 1998-09-15 Roche Colorado Corporation Preparation of mibefradil via an acetamide anion
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
US6380224B1 (en) * 1999-07-28 2002-04-30 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
AU2001235363A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Mibefradil analogues and their use
AU2001235364A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Tetrahydronaphtalene derivatives and their use
DE60124616T2 (de) * 2000-05-08 2007-09-13 Pfizer Products Inc., Groton Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors
FR2827862A1 (fr) * 2001-07-27 2003-01-31 Lipha Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique
CA2462913A1 (en) * 2001-10-10 2003-04-17 Aryx Therapeutics Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2005012297A1 (en) * 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
KR20070054644A (ko) * 2004-07-26 2007-05-29 액테리온 파마슈티칼 리미티드 미립자 제형으로 흡입된 일로프로스트에 의한 폐고혈압의치료
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2111863B1 (en) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
PL2152670T3 (pl) * 2007-04-27 2014-05-30 Idorsia Pharmaceuticals Ltd Mostkowane sześcioczłonowe związki pierścieniowe
MX2010011154A (es) * 2008-04-11 2010-12-21 Janssen Pharmaceutica Nv Tiazolopiridin-2-iloxi-fenilo y tiazolopirazin-2-iloxifenilaminas como moduladores de la leucotrieno a4 hidrolasa.
MX2010011459A (es) 2008-04-25 2010-11-12 Actelion Pharmaceuticals Ltd Derivados de bencimidazol como bloqueadores del canal de calcio.
US8314253B2 (en) 2008-10-22 2012-11-20 Actelion Pharmaceuticals Ltd. Bridged tetrahydronaphthalene derivatives
WO2010046729A2 (en) * 2008-10-23 2010-04-29 Actelion Pharmaceuticals Ltd Tetrahydronaphthalene compounds
EP3485881B1 (en) 2009-07-10 2024-03-13 President and Fellows of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
WO2011109464A1 (en) * 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
CN110545806A (zh) * 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
EP3860571A4 (en) 2018-10-03 2022-06-29 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN115850119A (zh) * 2022-11-26 2023-03-28 南昌大学 一种2-氯芳香胺类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914216A (en) * 1962-12-18 1975-10-21 Boehringer Sohn Ingelheim 1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones
BE793460A (fr) * 1971-12-29 1973-06-28 Boehringer Sohn Ingelheim Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h
NZ213651A (en) * 1984-10-11 1989-07-27 Hoffmann La Roche Tetrahydronapthalene derivatives and medicaments

Also Published As

Publication number Publication date
AU600769B2 (en) 1990-08-23
DE3775177D1 (de) 1992-01-23
ATE70267T1 (de) 1991-12-15
NO172237C (no) 1993-06-23
HUT60251A (en) 1992-08-28
IE60695B1 (en) 1994-08-10
NL970019I1 (nl) 1997-08-01
NO1998001I1 (no) 1998-01-09
DK171349B1 (da) 1996-09-16
AU8090987A (en) 1988-05-19
PT86130B (pt) 1990-11-20
JPS63139171A (ja) 1988-06-10
IL84407A (en) 1991-09-16
PH23919A (en) 1990-01-23
CN87107875A (zh) 1988-05-25
HK110494A (en) 1994-10-21
KR880006163A (ko) 1988-07-21
SG114194G (en) 1994-11-25
KR960004863B1 (en) 1996-04-16
MC1883A1 (fr) 1989-01-24
GR3004029T3 (es) 1993-03-31
EP0268148B1 (de) 1991-12-11
PT86130A (en) 1987-12-01
DE19775076I2 (de) 2001-08-09
MX173614B (es) 1994-03-18
US4808605A (en) 1989-02-28
LV5745A4 (lv) 1996-10-20
BG60937B2 (bg) 1996-06-28
MX9271A (es) 1993-09-01
FI94414B (fi) 1995-05-31
DK559987D0 (da) 1987-10-26
JP2504490B2 (ja) 1996-06-05
CA1319144C (en) 1993-06-15
DZ1142A1 (fr) 2004-09-13
DK559987A (da) 1988-05-15
LV5745B4 (lv) 1996-12-20
FI875024A (fi) 1988-05-15
NZ222474A (en) 1990-02-26
CS787487A2 (en) 1988-11-15
CS264350B2 (en) 1989-07-12
ZA878362B (en) 1988-05-16
HU215915B (hu) 1999-03-29
NO874757D0 (no) 1987-11-13
FI875024A0 (fi) 1987-11-13
IL84407A0 (en) 1988-04-29
NO172237B (no) 1993-03-15
ZW20087A1 (en) 1988-07-20
CN1028991C (zh) 1995-06-21
FI94414C (fi) 1995-09-11
EP0268148A1 (de) 1988-05-25
NL970019I2 (nl) 1997-11-03
IE873070L (en) 1988-05-14
NO874757L (no) 1988-05-16
CS394891A3 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
ES2040234T3 (es) Derivados del tetrahidronaftaleno y medicamentos que los contienen.
FI883807A (fi) Menetelmä farmakologisesti aktiivisten 7-(3-substituoitu-1-pyrrolidinyyli)-1-syklopropyyli-1,4-dihydro-4-okso-1,8-naftyridiini-3-karboksyylihappojohdannaisten valmistamiseksi
NO900306L (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
NO161971C (no) Analogifremgangsmaate ved fremstilling av tetrahydronaftalinderivater.
KR890014112A (ko) 퀴놀리진 및 퀴놀리지논 유도체의 심장 부정맥 치료용 의약품 제조에 있어서의 용도
IE44154L (en) 1,3,8-triazaspiro(4,5) decan-4-one derivatives
FI881075A0 (fi) Menetelmä optisesti aktiivisten, oikealle kiertävien okso-isoindolinyylijohdannaisten valmistamiseksi
NO171639C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolpyrazolderivater
US3555044A (en) Hexahydro-naphthoquinone semicarbazones
JPS57131788A (en) 1,7-naphthyridine derivative

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 268148

Country of ref document: ES